Erythropoietin (IPA pronunciation: , alternative pronunciations: ) or EPO is a glycoprotein hormone that is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. Also called hematopoietin or hemopoietin. It is produced by the kidney, and is the hormone regulating red blood cell production. Erythropoietin is available as a therapeutic agent produced by recombinant DNA technology in mammalian cell culture. It is used in treating anemia resulting from chronic renal failure or from cancer chemotherapy. Its use is also believed to be common as a blood doping agent in endurance sports such as bicycle racing, triathlons and marathon running.

Discovery and biological role

---

The existence of a humoral factor regulating red blood cell production was first postulated in 1906 based on transfusion experiments in rabbits. In 1950, the still unidentified erythropoietic factor was found to be stimulated in rats breathing a low-oxygen atmosphere, thus establishing the elements of its biological regulation. In the 1960s its source was identified as the kidneys. Human EPO was first purified from human urine by T. Miyake, C. K. Kung and E. Goldwasser at the University of Chicago in 1977. Limited quantitites of the native human protein were used experimentally to treat patients with anemia.

EPO has now been identified as a glycoprotein with a molecular mass of about 30,000 Daltons. It has a 165 amino acid chain with four oligosaccharide side chains and circulates in the blood plasma at a very low concentration (about 5 pmol/L).

More on [ Erythropoietin ]

Erythropoietin - Twitter Search

anemic Zabor, with chronic renal failure & developed antibodies to erythropoietin http://bit.ly/14Zg42 receives 5 units of packed-cell blood
NewportVet (Newport Beach Vet) Sun, 08 Nov 2009 00:28:39 -0000
anemic Zabor, with chronic renal failure & developed antibodies to erythropoietin http://bit.ly/14Zg42 receives 5 units of packed-cell blood
NEJM -- A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia http://ow.ly/zUSv
bloodmgmt (SABM) Fri, 06 Nov 2009 17:41:15 -0000
NEJM -- A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia http://ow.ly/zUSv
A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. in NEJM, Nov 5 2009 http://bit.ly/4dQrvs #pharmacology
PharmacoBlogie (PharmacoBlogie) Fri, 06 Nov 2009 11:22:36 -0000
A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. in NEJM, Nov 5 2009 http://bit.ly/4dQrvs #pharmacology
#NEJM: A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia: Background: We investig.. http://bit.ly/1dKIlI
medecinelitt (Médecine Littérature) Fri, 06 Nov 2009 09:46:40 -0000
#NEJM: A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia: Background: We investig.. http://bit.ly/1dKIlI
#NEJM : A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia: Background: We invest.. http://bit.ly/1dKIlI
medicinelitt (Medicine) Fri, 06 Nov 2009 08:12:33 -0000
#NEJM : A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia: Background: We invest.. http://bit.ly/1dKIlI
赤血球癆治療：　合成エリスロポイエチン受容体アゴニスト：Hematide: novel, synthetic, peptide-based erythropoietin-receptor agonist (Hemati.. http://bit.ly/185dEB
medicalcloud (medicalcloud) Thu, 05 Nov 2009 01:58:47 -0000
赤血球癆治療：　合成エリスロポイエチン受容体アゴニスト：Hematide: novel, synthetic, peptide-based erythropoietin-receptor agonist (Hemati.. http://bit.ly/185dEB

Subscribe to Erythropoietin RSS feed